NASDAQ: SCNXScienture Holdings Inc Stock
$0.18-0.08 (-30.77%)
Updated Oct 1, 2026
Scienture Holdings shares are trading... find out Why SCNX Price Moved with a free WallStreetZen account
Why Price MovedSCNX Price
$0.18
Fair Value Price
$0.04
Market Cap
$7.27M
52 Week Low
$0.18
52 Week High
$2.60
P/E
-0.08x
P/B
0.11x
P/S
16.88x
PEG
N/A
Dividend Yield
N/A
Revenue
$821.32k
Earnings
-$37.95M
Gross Margin
87.7%
Operating Margin
-4,490.54%
Profit Margin
-4,620.9%
Debt to Equity
0.37
Operating Cash Flow
-$14M
Beta
1.06
Next Earnings
Nov 11, 2026
Ex-Dividend
N/A
Next Dividend
N/A
SCNX Overview
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SCNX's potential to beat the market
- SCNX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical Retailer
Industry Rating
A
SCNX
RankedUnranked of 1
RankedUnranked of 1
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.67 | C | |
| $1.37 | – | |
| $0.11 | – |
Be the first to know about important SCNX news, forecast changes, insider trades & much more!
SCNX News
Overview
Due Diligence Score
–
Industry Average (18)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SCNX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SCNX ($0.18) is overvalued by 342.45% relative to our estimate of its Fair Value price of $0.04 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SCNX ($0.18) is not significantly undervalued (342.45%) relative to our estimate of its Fair Value price of $0.04 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SCNX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SCNX due diligence checks available for Premium users.
Valuation
SCNX fair value
Fair Value of SCNX stock based on Discounted Cash Flow (DCF)
Price
$0.18
Fair Value
$0.04
Overvalued by
349.95%
SCNX ($0.18) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SCNX ($0.18) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SCNX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SCNX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.08x
Industry
-6.65x
Market
48.27x
SCNX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.11x
Industry
29.51x
SCNX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SCNX's financial health
Profit margin
Revenue
$343.6k
Net Income
-$2.8M
Profit Margin
-821.3%
SCNX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SCNX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$87.7M
Liabilities
$23.6M
Debt to equity
0.37
SCNX's short-term assets ($9.20M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SCNX's long-term liabilities ($20.61M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SCNX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SCNX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.1M
Investing
$0.0
Financing
$10.8M
SCNX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SCNX vs Pharmaceutical Retailer Stocks
Scienture Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.